Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REALITY trial to reduce early mortality after ART initiation in advanced HIV
ISRCTN43622374Phase 3Completed
- Sponsor
- Medical Research Council
- Start
- Jun 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of trimethoprim + sulfamethoxazole, isoniazid, fluconazole, albendazole and azithromycin in human immunodeficiency virus infection (HIV) (6 arms), sponsored by Medical Research Council. Primary endpoint: Mortality through 24 weeks after ART initiation. Started Jun 2013; status: completed.
02
Drugs
trimethoprim + sulfamethoxazoleisoniazidfluconazolealbendazoleazithromycin
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ISRCTN43622374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN43622374.